The estimated Net Worth of Jerry B Gin is at least $315 Tisíc dollars as of 18 August 2022. Jerry Gin owns over 200,000 units of Vistagen Therapeutics stock worth over $315,000 and over the last 8 years he sold VTGN stock worth over $0. In addition, he makes $0 as Independent Director at Vistagen Therapeutics.
Jerry has made over 1 trades of the Vistagen Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 200,000 units of VTGN stock worth $36,000 on 18 August 2022.
The largest trade he's ever made was buying 200,000 units of Vistagen Therapeutics stock on 18 August 2022 worth over $36,000. On average, Jerry trades about 12,500 units every 0 days since 2016. As of 18 August 2022 he still owns at least 100,000 units of Vistagen Therapeutics stock.
You can see the complete history of Jerry Gin stock trades at the bottom of the page.
Dr. Jerry B. Gin Ph.D. serves as Independent Director of the Company. He was appointed to serve on our Board of Directors on March 29, 2016. Dr. Gin is currently the co-founder and CEO of Nuvora, Inc., a private company founded in 2006 with a drug delivery platform for the sustained release of ingredients through the mouth for such indications as dry mouth, biofilm reduction and sore throat/cough relief. Dr. Gin is also co-founder and Chairman of Livionex, a private platform technology company founded in 2009 and focused on oral care, ophthalmology and wound care. Previously, Dr. Gin co-founded Oculex Pharmaceuticals in 1993, which developed technology for controlled release delivery of drugs to the interior of the eye, specifically to treat macular edema, and served as President and CEO until it was acquired by Allergan in 2003. Prior to forming Oculex, Dr. Gin co-founded and took public ChemTrak, which developed a home cholesterol test commonly available in drug stores today. Prior to ChemTrak, Dr. Gin was Director of New Business Development and Strategic Planning for Syva, the diagnostic arm of Syntex Pharmaceuticals, Director for Pharmaceutical and Diagnostic businesses for Dow Chemical, and Director of BioScience Labs (now Quest Laboratories), the clinical laboratories of Dow Chemical. Dr. Gin received his Bachelor’s degree in Chemistry from the University of Arizona, his Ph.D. in Biochemistry from the University of California, Berkeley, his MBA from Loyola College, and conducted his post-doctoral research at the National Institutes of Health.
Jerry Gin is 76, he's been the Independent Director of Vistagen Therapeutics since 2018. There are 2 older and 13 younger executives at Vistagen Therapeutics. The oldest executive at Vistagen Therapeutics Inc. is Jon Saxe, 84, who is the Independent Chairman of the Board.
Jerry's mailing address filed with the SEC is C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 8 years, insiders at Vistagen Therapeutics have traded over $147,300 worth of Vistagen Therapeutics stock and bought 1,944,506 units worth $18,208,989 . The most active insiders traders include Healthcare Capital Partners..., Capital Lp Commodore a Jon S Saxe. On average, Vistagen Therapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $378,372. The most recent stock trade was executed by Capital Lp Commodore on 7 August 2023, trading 775,756 units of VTGN stock currently worth $17,958,751.
we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
Vistagen Therapeutics executives and other stock owners filed with the SEC include: